Stock DASA3 DIAGNOSTICOS DA AMÉRICA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Diagnosticos da América S.A.

Equities

DASA3

BRDASAACNOR1

Healthcare Facilities & Services

Market Closed - Sao Paulo
Other stock markets
 16:07:51 2024-05-03 EDT 		5-day change 1st Jan Change
4.69 BRL -0.21% Intraday chart for Diagnosticos da América S.A. +1.96% -51.25%
03-28 Transcript : Diagnósticos da América S.A., Q4 2023 Earnings Call, Mar 28, 2024
03-27 Diagnósticos da América S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 34,851 18,485 7,686 7,186 3,504 - -
Enterprise Value (EV) 1 34,851 26,409 7,686 16,167 15,096 13,855 13,603
P/E ratio - -90.8 x -19.8 x -6.16 x 31.3 x 5.52 x -
Yield - 0.89% - - 0.64% 3.13% -
Capitalization / Revenue 4.95 x 1.77 x 0.59 x 0.46 x 0.22 x 0.21 x 0.2 x
EV / Revenue 4.95 x 2.53 x 0.59 x 1.04 x 0.97 x 0.83 x 0.78 x
EV / EBITDA - 20.6 x 3.54 x 6.91 x 5.42 x 4.44 x 3.97 x
EV / FCF - -7.23 x - -9.11 x 33.8 x 14.6 x 11.1 x
FCF Yield - -13.8% - -11% 2.96% 6.85% 9%
Price to Book - 2.51 x - 0.99 x 0.45 x 0.45 x -
Nbr of stocks (in thousands) 480,705 547,872 559,827 746,960 747,048 - -
Reference price 2 72.50 33.74 13.73 9.620 4.690 4.690 4.690
Announcement Date 21-03-07 22-03-28 23-03-28 24-03-28 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7,039 10,419 13,129 15,557 15,587 16,628 17,519
EBITDA 1 - 1,282 2,168 2,339 2,785 3,124 3,427
EBIT 1 - 351.7 1,102 913.3 1,523 1,900 2,091
Operating Margin - 3.38% 8.39% 5.87% 9.77% 11.43% 11.93%
Earnings before Tax (EBT) 1 - -374.2 -578.8 -996 -86.51 582.5 332
Net income 1 -150.8 -226.6 -386.9 -1,130 4.381 475.3 478.2
Net margin -2.14% -2.17% -2.95% -7.26% 0.03% 2.86% 2.73%
EPS 2 - -0.3715 -0.6932 -1.561 0.1500 0.8500 -
Free Cash Flow 1 - -3,654 - -1,775 447 949 1,224
FCF margin - -35.07% - -11.41% 2.87% 5.71% 6.99%
FCF Conversion (EBITDA) - - - - 16.05% 30.38% 35.72%
FCF Conversion (Net income) - - - - 10,203.43% 199.65% 255.93%
Dividend per Share 2 - 0.3012 - - 0.0300 0.1467 -
Announcement Date 21-03-07 22-03-28 23-03-28 24-03-28 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3
Net sales 1 2,721 2,673 3,136 3,288 3,425 3,279 3,534 3,631 3,769 3,777 3,741 3,903 4,046
EBITDA 1 543.7 222.9 560.5 512.3 607.3 457.6 615.7 526.1 660.8 438 665.9 - -
EBIT 1 299 -39.21 288.4 227.3 307.9 208 306 215.4 331 60.98 447.5 404.4 511.7
Operating Margin 10.99% -1.47% 9.2% 6.91% 8.99% 6.34% 8.66% 5.93% 8.78% 1.61% 11.96% 10.36% 12.65%
Earnings before Tax (EBT) - - - - - - - - - - - - -
Net income 1 73.6 -167.1 37.11 -120.1 -89.36 -214.6 -166 -282.1 -180.5 -495 -30 - -
Net margin 2.7% -6.25% 1.18% -3.65% -2.61% -6.54% -4.7% -7.77% -4.79% -13.11% -0.8% - -
EPS 2 0.1281 -0.2630 0.0636 -0.2145 -0.1592 -0.3853 -0.3019 -0.3803 - - 0.0500 0.0200 0.1100
Dividend per Share - - - - - - - - - - - - -
Announcement Date 21-11-12 22-03-28 22-05-12 22-08-11 22-11-14 23-03-28 23-05-12 23-08-10 23-11-09 24-03-28 - - -
1BRL in Million2BRL
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 7,924 - 8,981 11,592 10,352 10,099
Net Cash position 1 - - - - - - -
Leverage (Debt/EBITDA) - 6.183 x - 3.84 x 4.162 x 3.314 x 2.947 x
Free Cash Flow 1 - -3,654 - -1,775 447 949 1,224
ROE (net income / shareholders' equity) - -4.09% - -16.2% -4% 6.43% 8%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 13.50 - 9.740 10.50 10.50 -
Cash Flow per Share 2 - 2.320 - -1.290 1.700 - -
Capex 1 - 4,952 - 727 841 774 860
Capex / Sales - 47.53% - 4.67% 5.4% 4.65% 4.91%
Announcement Date 21-03-07 22-03-28 23-03-28 24-03-28 - - -
1BRL in Million2BRL
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Diagnosticos da América S.A.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
4.69 BRL
Average target price
9.556 BRL
Spread / Average Target
+103.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
DIAGNOSTICOS DA AMÉRICA S.A. Stock Diagnosticos da América S.A.
-51.25% 691M
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.70% 81.4B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-29.20% 70.18B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+9.72% 29.08B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.43% 16.97B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-0.43% 16.96B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-0.31% 15.26B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+3.42% 12.41B
PURE HEALTH HOLDING Stock Pure Health Holding
-30.70% 11.95B
REDE D'OR SÃO LUIZ S.A. Stock Rede D'Or São Luiz S.A.
-6.75% 11.93B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. DASA3 Stock
  4. Financials Diagnosticos da América S.A.